$15.45
3.14% today
Nasdaq, Feb 28, 05:17 pm CET
ISIN
US98401F1057
Symbol
XNCR

Xencor, Inc. Stock price

$14.98
-4.25 22.10% 1M
-2.16 12.60% 6M
-8.00 34.81% YTD
-11.54 43.51% 1Y
-16.33 52.16% 3Y
-17.21 53.46% 5Y
-0.62 3.97% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
+0.60 4.17%
ISIN
US98401F1057
Symbol
XNCR
Sector
Industry

Key metrics

Market capitalization $1.05b
Enterprise Value $743.88m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6.85
P/S ratio (TTM) P/S ratio 9.65
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -25.19%
Revenue (TTM) Revenue $108.67m
EBIT (operating result TTM) EBIT $-193.96m
Free Cash Flow (TTM) Free Cash Flow $-139.60m
Cash position $542.98m
EPS (TTM) EPS $-3.44
P/E forward negative
P/S forward 16.43
EV/Sales forward 11.46
Short interest 12.64%
Show more

Is Xencor, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Xencor, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

12 Analysts have issued a Xencor, Inc. forecast:

11x Buy
92%
1x Sell
8%

Analyst Opinions

12 Analysts have issued a Xencor, Inc. forecast:

Buy
92%
Sell
8%

Financial data from Xencor, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
109 109
25% 25%
100%
- Direct Costs 12 12
18% 18%
11%
96 96
29% 29%
89%
- Selling and Administrative Expenses 37 37
25% 25%
34%
- Research and Development Expense 241 241
0% 0%
222%
-182 -182
34% 34%
-167%
- Depreciation and Amortization 12 12
18% 18%
11%
EBIT (Operating Income) EBIT -194 -194
33% 33%
-178%
Net Profit -213 -213
79% 79%
-196%

In millions USD.

Don't miss a Thing! We will send you all news about Xencor, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Xencor, Inc. Stock News

Neutral
Business Wire
one day ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the fourth quarter and full year ended December 31, 2024 and provided clinical updates and priorities for 2025. “In 2024, we began rebalancing our pipeline to focus on ...
Positive
Market Watch
10 days ago
The co-chief investment officers at Neuberger Berman see a new dynamic in the stock market as investors move on from inflation worries.
Neutral
Business Wire
3 months ago
PASADENA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today announced that company management will participate at multiple upcoming investor conferences: Piper Sandler 36th Annual Healthcare Conference Date: Tuesday, December 3, 2024 Presentation Time: 2:0...
More Xencor, Inc. News

Company Profile

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA.

Head office United States
CEO Bassil Dahiyat
Employees 280
Founded 1997
Website www.xencor.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today